SCHEMBL5214527

SCHEMBL5214527

CCN(CC)C(=O)N(C1CCCCCC1)C1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2)N[C@H]2CC[C@@H](NC(=O)O)CC2)CC1

nearest known ligand 0.43

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MC4R P32245 14/20 0.43
AVPR1A P37288 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5458234 1.00 MC4R (0.43) MC4RAVPR1AL3MBTL1KDM4E
SCHEMBL5214537 1.00 MC4R (0.43) MC4RAVPR1AL3MBTL1KDM4E
SCHEMBL5197965 0.91 MC4R (0.44) MC4R
SCHEMBL5449594 0.91 CYP51A1 (0.44) MC4R
SCHEMBL5453848 0.90 MC4R (0.45) MC4R
SCHEMBL5451683 0.90 MC4R (0.45) MC4R
SCHEMBL5465387 0.90 MC4R (0.45) MC4R
SCHEMBL5465381 0.90 MC4R (0.45) MC4R
SCHEMBL5452839 0.90 MC4R (0.45) MC4R
SCHEMBL5458096 0.90 MC4R (0.41) MC4RAVPR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191364-A1 AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-08-16 US disclosed
EP-1786809-A2 AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF AS MELANOCORTIN RECEPTOR AGONISTS Sanofi-Aventis (FR) 2007-05-23 EP disclosed
WO-2006021656-A2 AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF AS MELANOCORTIN RECEPTOR AGONISTS SANOFI-AVENTIS (FR) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191364-A1 AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF MC4R, MC5R, TAAR5 MC4R 1/4885AVPR1A 12/4885L3MBTL1 3962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.